〜かかりつけ医でみる〜　骨粗鬆症Q&A

出版社： 先端医学社
著者：
発行日： 2010-01-15
分野： 臨床医学：外科  >  整形外科学
ISBN： 9784884076122
電子書籍版： 2010-01-15 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,400 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

商品紹介

本書では、実診療に即した問いかけに対し、骨粗鬆症、骨代謝学の第一線の専門家が全４０項目の「Q＆A」形式で実践的にわかりやすく解説している。すべてのかかりつけ医の診療机に置いておきたい一冊。

目次

  • 〜かかりつけ医でみる〜　骨粗鬆症Q&A

    ―目次―

    Part 1　骨粗鬆症の現状とその課題をみる
    　Q.1　骨粗鬆症とはどのような疾患か最新の
    　　　　定義について教えてください．
    　　　また，わが国の骨粗鬆症の患者さんは
    　　　　どのくらいいるか教えてください．
    　Q.2　骨粗鬆症の患者さんは女性が多いとのことですが，女性
    　　　　骨粗鬆症と男性骨粗鬆症の違いについて教えてください．
    　Q.3　かかりつけ医が骨粗鬆症の積極的治療・薬物介入をする
    　　　　ことにはどのような意義がありますか？
    　　　　日常生活における QOL 向上の視点から教えてください．

    Part 2　骨粗鬆症の病態と診断をみる
    　Q.4　近年，CKD−MBD という概念が提唱されていますが，慢性
    　　　　腎臓病が骨粗鬆症に与える影響について教えてください．
    　Q.5　糖尿病と骨粗鬆症発症に関連性はありますか？
    　　　　糖尿病が骨代謝に与える影響について教えてください．
    　Q.6　飲酒・喫煙などの生活習慣と骨粗鬆症や骨折の発生に
    　　　　関連性はありますか？また，骨粗鬆症にならないために
    　　　　どのような生活習慣に気をつければよいか教えてください．
    　ほか

    Part 3　骨粗鬆症の治療戦略を探る
    　Q.14 『骨粗鬆症の予防と治療ガイドライン 2006 年版』での
    　　　　骨粗鬆症の治療開始基準とその根拠を教えてください．
    　Q.15 骨粗鬆症の治療時に避けたほうがよい食物などは
    　　　　ありますか？また，積極的に摂取したほうがよい食物など
    　　　　があれば教えてください．
    　Q.16 骨粗鬆症患者さんに対する運動療法はどのように
    　　　　すすめればよいか教えてください．
    　Q.17 骨粗鬆症患者さんに対する治療薬の選択について
    　　　　教えてください．
    　ほか

    Part 4　治療に注意を要する骨粗鬆症患者さんの治療戦略を探る
    　Q.25 甲状腺機能亢進症を合併した骨粗鬆症患者さんに対する
    　　　　治療法・治療薬の選択について教えてください．
    　Q.26 骨粗鬆症治療において，関節リウマチ・呼吸器疾患等で
    　　　　長期間ステロイドを使用している患者さんへの
    　　　　注意点・治療戦略について教えてください．
    　Q.27 糖尿病を伴った患者さんの治療法に注意点はありますか？
    　　　　また，生活習慣指導で気をつけるべき点がありましたら
    　　　　　教えてください．
    　Q.28 慢性腎臓病を合併する骨粗鬆症患者さんへの
    　　　　治療法・治療薬の選択について教えてください．
    　ほか

    Part 5　きめの細かい服薬指導のために知識を得る
    　Q.32 処方薬の有効性，安全性をどのように服薬指導のなかで
    　　　　伝えたらよいか教えてください．
    　Q.33 ビスフォスフォネート製剤服用時に起こりうる副作用
    　　　　としてどのようなものがあるか教えてください．
    　　　　また，週 1 回製剤と 1 日 1 回製剤では副作用の発現に
    　　　　差はあるか教えてください．
    　Q.34 ステロイド性骨粗鬆症の服薬指導で注意すべき点を
    　　　　教えてください．
    　Q.35 骨粗鬆症患者さんへ薬物治療を開始する際の説明ポイント
    　　　　は何か教えてください．
    　　　　また，自己判断で服薬を中断する患者さんへの
    　　　　対処方法を教えてください．

    Part 6　骨粗鬆症治療における各科の役割を探る
    　Q.36 ビスフォスフォネート系薬剤関連顎骨壊死（BRONJ）
    　　　　について教えてください．
    　　　　また，医科・歯科の連携はどのようにおこなえばよいか
    　　　　教えてください．
    　Q.37 骨粗鬆症患者さんは，さまざまな生活習慣病を伴っている
    　　　　ことが多いとのことですが，骨粗鬆症患者さんの内科診療
    　　　　における課題について教えてください．
    　Q.38 骨粗鬆症患者さんを診察する医師の大半が整形外科医で
    　　　　あるといわれていますが，整形外科での課題と他科との
    　　　　連携について教えてください．
    　Q.39 骨粗鬆症治療における産婦人科の果たす役割と
    　　　　ライフスタイルの管理の重要性について教えてください．
    　Q.40 大腿骨近位部骨折のクリティカルパスについて，
    　　　　現在どのような取り組みがなされているか教えてください．

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[Part1] 骨粗鬆症の現状とその課題をみる

P.13 掲載の参考文献
1) Albright F, Smith PH, Richardson AM:Postmenopausal osteoporosis:its clinical feature. JAMA 116:2465-2474, 1941
 
2) Consensus development conference:prophylaxis and treatment of osteoporosis. Am J Med 90:107-110, 1991
PubMed
3) Li Z, Meredith MP, Hoseyni MS et al:A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175-3188, 2001
PubMed
4) Cummings SR, Karpf DB, Harris F et al:Improvement in spine bone density and reduction in risk of ver-tebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289, 2002
 
5) Sarkar S, Mitlak BH, Wong M et al:Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10, 2002
PubMed
6) Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 17:1-45, 2000
PubMed
7) 内閣府:2006年度版高齢社会白書 <http://www8.cao.go.jp/kourei/whitepaper/w-2006/zenbun/18index.html>
 
8) 藤原佐枝子, 増成直美, 児玉和紀ほか:腰椎・大腿骨骨塩量カットオフ値を使った骨粗鬆症有病率の検討. Osteoporosis Jpn 5:223-226, 1997
 
9) 山本逸雄:骨粗鬆症人口の推定. Osteoporosis Jpn 7:10-11, 1999
 
10) Fujiwara S, Mizuno S, Ochi Y et al:The incidence of thoracic vertebral fractures in a Japanese popula-tion, Hiroshima and Nagasaki, 1958-1986, J Clin Epidemiol 44:1007-1014, 1991
 
11) Yoshimura N, Kinoshita H, Oka H et al:Cumulative incidence and changes in prevalence of vertebral fractures in a rural Japanese community:a 10-year follow-up of the Miyama cohort. Arch Osteoporos 1:43-49, 2006
 
P.18 掲載の参考文献
1) Seeman E:Sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab 86:4576-4584, 2001
PubMed
2) Seeman E:Pathogenesis of osteoporosis. J Appl Physiol 95:2142-2151, 2003
 
3) Donaldson LJ, Cook A, Thomson RG:Incidence of fractures in a geographically defined population. J Epidemiol Community Health 44:241-245, 1990
 
4) Orwoll ES:Osteoporosis in men. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism(7th ed), ed by Rosen CJ, ASBMR, Washington DC, 2008, pp.286-289
 
5) Bilezikian JP:The role of estrogens in male skeletal development. Reprod Fertil Dev 13:253-259, 2001
PubMed
6) Ohlsson C, Vandenput L:The role of estrogens for male bone health. Eur J Endocrinol 160:883-889, 2009
PubMed
7) Riggs BL, Khosla S, Melton LJ 3rd:A unitary model for involutional osteoporosis:estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773, 1998
 
P.22 掲載の参考文献
1) 吉村典子:骨粗鬆症発生頻度の動向. medicina 45:401-405, 2008
 
2) 山口徹:骨粗鬆症の内科的な合併症(逆流性食道炎など). Osteoporosis Jpn 17:267-270, 2009
Medical*Online
3) 中村利孝:骨粗鬆症におけるQOL評価の重要性と今後の展開について. Osteoporosis Jpn 15:520-523, 2007
Medical*Online
4) 増成直美:高齢者における身長低下とQOL. Clin Calcium 18:1148-1153, 2008
 
5) 村木重之, 吉村典子:骨粗鬆症とそれによる骨折の頻度と予後. Clin Calcium 16:1431-1437, 2006
 
6) 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006
 
7) 塩井淳:動脈硬化・血管石灰化と骨粗鬆症. Osteoporosis Jpn 16:417-420, 2008
Medical*Online

[Part2] 骨粗鬆症の病態と診断をみる

P.27 掲載の参考文献
1) CKD診療ガイド, 日本腎臓学会編, 東京医学社, 東京, 2007
 
2) Nickolas TL, McMahon DJ, Shane E et al:Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17:3223-3232, 2006
PubMed
3) Coresh J, Astor BC, Greene T et al:Prevalence of chronic kidney disease and decreased kidney func-tion in the adult US population:Third National health and Nutrition Examination Survey. Am J Kidney Dis 41:1-12, 2003
 
4) Atsumi K, Kushida K, Yamazaki K et al:Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287-293, 1999
PubMed
5) ガイドラインサポートハンドブック 慢性腎臓病に伴う骨ミネラル代謝異常(CKD-MBD), 深川雅史編, 医薬ジャーナル社, 大阪, 2007
 
6) CKD-MBDハンドブック, 深川雅史編著, 日本メディカルセンター, 東京, 2009
 
P.31 掲載の参考文献
1) Vestergaard P:Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 18:427-444, 2007
PubMed
2) Yamamoto M, Yamaguchi T, Yamauchi M et al:Diabetic patients have an increased risk of vertebral frac-tures independent of BMD or diabetic complications. J Bone Miner Res 24:702-709, 2009
PubMed
3) Yamamoto M, Yamaguchi T, Yamauchi M et al:Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in type 2 diabetic women. Calcif Tissue Int 80:353-358, 2007
 
4) Saito M, Fujii K, Mori Y et al:Role of collagen enzymatic and glycation induced cross-links as a determi-nant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17:1514-1523, 2006
 
5) 山本昌弘, 山内美香, 矢野彰三ほか:閉経後2型糖尿病患者におけるHip structure analysisによる大腿骨皮質骨構造の解析(第一報). Osteoporosis Jpn 16(Suppl 1):133, 2008
 
6) Kanazawa I, Yamaguchi T, Yamauchi M et al:Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:3031-3037, 2009
PubMed
7) Ogawa N, Yamaguchi T, Yano S et al:The Combination of high glucose and advanced glycation end-products(AGEs)inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39:871-875, 2007
PubMed
8) Yamamoto M, Yamaguchi T, Yamauchi M et al:Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 93:1013-1019, 2008
PubMed
9) Cauley JA, Thompson DE, Ensrud KC et al:Risk of mortality following clinical fractures. Osteoporos Int 11:556-561, 2000
PubMed
P.36 掲載の参考文献
1) 厚生労働省:公衆衛生審議会 生活習慣に着目した疾病対策の基本的方向性について(意見具申)1996.12.18.<http://www1.mhlw.go.jp/shingi/1217-1.html>
 
2) 伊木雅之, 久保田恵, 吉村典子ほか:エビデンスに基づく骨折・骨粗鬆症予防. 日衛誌 58:311-356, 2003
 
3) 地域保健におけるエビデンスに基づく骨折・骨粗鬆症予防ガイドライン, 伊木雅之編, 日本公衆衛生協会, 東京, 2004
 
4) 骨粗鬆症による骨折の危険因子. 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006, pp.34-35
 
5) De Laet C, Kanis JA, Oden A et al:Body mass index as a predictior of fracture risk:a meta-analysis. Osteoporos Int 16:1330-1338, 2005
 
6) Kanis JA, Borgstrom F, De Laet C et al:Assessment of fracture risk. Osteoporos Int 16:581-589 2005
PubMed
7) Kanis JA, Johnell O, De Laet C et al:A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375-382, 2004
PubMed
8) Kanis JA, Johansson H, Oden A et al:A family history of fracture and fracture risk:a meta-analysis. Bone 35:1029-1037, 2004
 
9) Kanis JA, Johnell O, Oden A et al:Smoking and fracture risk:a meta-analysis. Osteoporos Int 16:155-162, 2005
 
10) Kanis JA, Johansson H, Johnell O et al:Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737-742, 2005
PubMed
11)Johnell O, Kanis JA, Oden A et al:Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194, 2005
PubMed
12) FRAX(R)WHO骨折リスク評価ツール <http://www.shef.ac.uk/FRAX/index_JP.htm>
 
13) 厚生労働省:平成18年国民健康・栄養調査結果の概要. <http://www.mhlw.go.jp/houdou/2008/04/dl/h0430-2c.pdf>
 
14) 健康日本21:各論(5. アルコール) <http://www.kenkounippon21.gr.jp/kenkounippon21/about/kakuron/index.html>
 
P.41 掲載の参考文献
1) Devlin H, Karayianni K, Mitsea A et al:Diagnosing osteoporosis by using dental panoramic radiographs:the OSTEODENT project, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:821-828, 2007
PubMed
2) Taguchi A, Tsuda M, Ohtsuka M et al:Use of dental panoramic radiographs in identifying younger post-menopausal women with osteoporosis. Osteoporos Int 17:387-394, 2006
 
3) Taguchi A, Ohtsuka M, Tsuda M et al:Risk of vertebral osteoporosis in post-menopausal women with alterations of the mandible. Dentomaxillofac Radiol 36:143-148, 2007
PubMed
4) Taguchi A, Sanada M, Krall E et al:Relationship between dental panoramic radiographic findings and biochemical markers of bone turnover. J Bone Miner Res 18:1689-1694, 2003
PubMed
5) Bollen AM, Taguchi A, Hujoel PP et al:Case-control study on self-reported osteoporotic fractures and mandibular cortical bone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90:518-524, 2000
PubMed
6) Taguchi A, Fujiwara S, Masunari N et al:Self-reported number of remaining teeth is associated with bone mineral density of the femoral neck, but not of the spine, in Japanese men and women. Osteoporos Int 15:842-846, 2004
 
7) Phipps KR, Chan BK, Madden TE et al:Longitudinal study of bone density and periodontal disease in men. J Dent Res 86:1110-1114, 2007
 
8) Taguchi A, Sanada M, Suei Y et al:Effect of estrogen use on tooth retention, oral bone height, and oral bone porosity in Japanese postmenopausal women. Menopause 11:556-562, 2004
PubMed
9) 新谷雅史, 山下健, 田口明ほか:閉経後女性に対する塩酸ラロキシフェンの歯牙喪失に対する影響. SERM 5:116-117, 2007
 
P.45 掲載の参考文献
1) Siminoski K, Jiang G, Adachi JD et al:Accuracy of height loss during prospective monitoring for detec-tion of incident vertebral fractures. Osteoporos Int 16:403-410, 2005.
 
2) 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006
 
3) Green AD, Colon-Emeric CS, Bastian L et al:Does this woman have osteoporosis? JAMA 292:2890-2900, 2004
PubMed
4) Koh LKH, Sedrine WB, Torralba TP et al:A simple tool to indentify Asian women at increased risk of osteoporosis. Osteoporos Int 12:699-705, 2001
 
5) FRAX(R)WHO骨折リスク評価ツール <http://www.shef.ac.uk/FRAX/index_JP.htm>
 
P.50 掲載の参考文献
1) 高柳涼一, 大中佳三:グルココルチコイドの骨代謝作用機構. 骨粗鬆症治療 5:10-15, 2006
Medical*Online
2) Hofbauer LC, Rauner M:Live and let die:molecular effects of glucocorticoids on bone cells. Mol Endo-crinol 23:1525-1531, 2009
 
3) Ohnaka K, Tanabe M, Kawate H et al:Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177-181, 2005
PubMed
4) Wang FS, Ko JY, Yeh DW et al:Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteo-blast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149:1793-1801, 2008
 
5) Lane NE, Yao W, Balooch M et al:Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estro-gen-deficient mice. J Bone Miner Res 21:466-476, 2006
 
6) Yao W, Cheng Z, Pham A et al:Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485-3497, 2008
PubMed
7) Hofbauer LC, Zeitz U, Schoppet M et al:Prevention of glucocorticoid-induced bone loss in mice by inhi-bition of RANKL. Arthritis Rheum 60:1427-1437, 2009
 
P.53 掲載の参考文献
1) 折茂 肇, 林 泰史, 福永仁夫ほか:原発性骨粗鬆症の診断基準(2000年度改訂版). 日骨代謝会誌 18:76-82, 2001
Medical*Online
2) Nawata H, Soen S, Takayanagi R et al:Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis:Guidelines on the management and treatment of glucocorticoid-induced osteo-porosis of the Japanese Society for Bone and Mineral Research(2004). J Bone Miner Metab 23:105-109, 2005
 
3) 福永仁夫, 山内広世, 西川 憲:II骨量測定装置に関する調査. 骨粗鬆症による要介護状態発生の予防にむけて-今後の骨粗鬆症検診のあり方についての調査・研究報告書-平成19年度老人保健健康増進等事業, 骨粗鬆症財団, 東京, 2008, p.5
 
4) 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006
 
5) 骨塩量測定機器の互換性検討委員会成果報告. Osteoporosis Jpn 10:411-427, 2002
 
6) 楊 鴻生:標準化の基となった各QUS機器の測定結果. Osteoporosis Jpn 17:165-169, 2009
Medical*Online
7) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy:Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795, 2001
PubMed
P.59 掲載の参考文献
1) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy:Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795, 2001
PubMed
2) 骨粗鬆症の予防と治療のガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006
 
3) Green AD, Colon-Emeric CS, Bastian L et al:Does this woman have osteoporosis? JAMA 292:2890-2900, 2004
PubMed
P.64 掲載の参考文献
1) Wasnich RD, Miller PD:Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236, 2000
PubMed
2) Ettinger B, Black DM, Mitlak BH et al;Multiple Outcomes of Raloxifene Evaluation(MORE)Investigators:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized clinical trial. JAMA 282:637-645, 1999
PubMed
3) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy:Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795, 2001
PubMed
4) Weinstein RS:True strenghth. J Bone Miner Res 15:621-625, 2000
 
5) Beck TJ, Looker AC, Ruff CB et al:Structural trends in the aging femoral neck and proximal shaft:Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res 15:2297-2304, 2000
 
6) Singh M, Nagrath AR, Maini PS:Changes in trabecular pattern of the upper end of the femur as an index of osteoporosis. J Bone Joint Surg Am 52:457-467, 1970
 
7) Wehrli F, Hwang S, Ma J et al:Cancellous bone volume and structure in the forearm:noninvasive assessment with MR microimaging and image processing. Radiology 206:347-357, 1998
PubMed
8) Majumdar S, Link TM, Augat P et al:Trabecular bone architecture in the distal radius using magnetic resonance imaging in subjects with fractures of the proximal femur. Osteoporos Int 10:231-239, 1999
PubMed
9) Chestnut CH III, Majumdar S, Newitt DC et al:Effects of salmon calcitonin on trabecular microarchitec-ture as determined by magnetic resonsnce imaging:results from the QUEST study. J Bone Miner Res 20:1548-1561, 2005
 
10) Ito M, Ikeda K, Nishiguchi M et al:Multi-detector-row CT imaging of vertebral microstructure for evalua-tion of fracture risk. J Bone Miner Res 20:1828-1836, 2005
 
P.67 掲載の参考文献
1) Kanis JA, Borgstrom F, De Laet C et al:Assessment of fracture risk. Osteoporos Int 16:581-589, 2005
PubMed
2) Fujiwara S, Nakamura T, Orimo H et al:Development of application of a Japanese model of the WHO fracture risk assessment tool(FRAX(TM)). Osteoporos Int 19:429-435, 2008
 
3) Kanis JA, Oden A, Johnell O et al:The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033-1046, 2007
PubMed

[Part3] 骨粗鬆症の治療戦略を探る

P.74 掲載の参考文献
1) Consensus Development Conference V, 1993 Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 90:646-650, 1994
 
2) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy:Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795, 2001
PubMed
3) Kanis JA:Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936, 2002
PubMed
4) 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006
 
5) 折茂 肇, 林 泰史, 福永仁夫ほか:原発性骨粗鬆症の診断基準(2000年度改訂版). 日骨代謝会誌 18:76-82, 2001
Medical*Online
6) Nguyen TV, Eisman JA:Genetics of fracture:challenges and opportunities. J Bone Miner Res 15:1253-1256, 2000
PubMed
7) Aerssens J, Dequeker J, Peeters J et al:Polymorphisms of the VDR, ER and COLIA1 genes and osteo-porotic hip fracture in elderly postmenopausal women. Osteoporos Int 11:583-591, 2000
 
8) Andrew T, Antonioades L, Scurrah KJ et al:Risk of wrist fracture in women is heritable and is influenced by genes that are largely independent of those influencing BMD. J Bone Miner Res 20:67-74, 2005
 
9) Chang JT, Morton SC, Rubenstein LZ et al:Interventions for the prevention of falls in older adults:sys-tematic review and meta-analysis of randomised clinical trials. BMJ 328:680, 2004
 
P.78 掲載の参考文献
1) 白木正孝, 上西一弘, 石田裕美ほか:骨粗鬆症の人の食事. 女子栄養大学出版部, 東京, 2003
 
2) 厚生労働省:日本人の食事摂取基準(2005年版), 第一出版編集部編, 第一出版, 東京, 2005
 
3) 厚生労働省:日本人の食事摂取基準(2010年版) <http://www.mhlw.go.jp/bunya/kenkou/sessyu-kijun.html>
 
4) 農林水産省:食事バランスガイド <http://www.maff.go.jp/j/balance_guide/index.html>
 
5) Heaney RP, Weaver CM, Recker RR:Calcium absorbability from spinach. Am J Clin Nutr 47:707-709, 1988
PubMed
6) 上西一弘, 江澤郁子, 梶本雅俊ほか:日本人若年成人女性における牛乳, 小魚(ワカサギ, イワシ), 野菜(コマツナ, モロヘイヤ, オカヒジキ)のカルシウム吸収率. 日栄・食糧会誌 51:259-266, 1998
Medical*Online
7) WHO Technical Report Series 921:Prevention and management of osteoporosis:Report of a WHO Scien-tific Group, WHO, Geneva, 2003
 
8) 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006
 
9) Kaneki M, Hodges SJ, Hosoi T et al:Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2:possible implications for hip-fracture risk. Nutrition 17:315-321, 2001
PubMed
10) 白木正孝, 青木長寿, 山崎典美ほか:電気化学発光免疫法による血清中低力ルボキシル化オステオカルシン(ucOC)測定キットの臨床的有用性の検討-カットオフ値の設定と骨粗鬆症患者におけるビタミンK2剤選択時の有用性の検討-. 医学と薬学 57:537-546, 2007
 
11) International Osteoporosis Foundation:About Osteoporosis:Prevention:Nutrition <http://www.iofbonehealth.org/patients-public/about-osteoporosis/prevention/nutrition.html>
 
P.84 掲載の参考文献
1) Aloia JF, Cohn SH, Ostuni JA et al:Prevention of involutional bone loss by exercise. Ann Intern Med 89:356-358, 1978
PubMed
2) Dalsky GP, Stocke KS, Ehsani AA et al:Weight-bearing exercise training and lumbar bone mineral con-tent in postmenopausal women. Ann Int Med 108:824-828, 1988
 
3) Granhed H, Jonson R, Hansson T:The loads on the lumbar spine during extreme weight lifting. Spine 12:146-149, 1987
PubMed
4) 林 泰史:骨粗鬆症と運動. 日医会誌 104:1175-1178, 1990
 
5) Notelovitz M, Martin D, Tesar R et al:Estrogen therapy and variable-resistance weight training increase bone mineral in surgically menopausal women. J Bone Miner Res 6:583-590, 1991
PubMed
6) Smith EL Jr, Reddan W, Smith PE:Physical activity and calcium modalities for bone mineral increase in aged women. Med Sci Sports Exerc 13:60-64, 1981
PubMed
7) Jones HH, Priest JD, Hayes WC et al:Humeral hypertrophy in response to exercise. J Bone Joint Surg Am 59:204-208, 1977
PubMed
8) 武藤芳照:転倒予防の医学的基礎. 転倒予防教室-転倒予防への医学的対応-, 武藤芳照, 黒柳律雄, 上野勝則ほか編, 日本医事新報社, 東京, 1999, pp.1-21
 
9) Sinaki M, Mikkelsen BA:Postmenopausal spinal osteoporosis:flexion versus extension exercise. Arch Phys Med Rehabil 65:593-596, 1984
PubMed
10) Frost HM:Vital biomechanics:proposed general concepts for skeletal adaptations to mechanical usage. Calcif Tissue Int 42:145-156, 1988
PubMed
11) Turner CH:Homeostatic control of bone structure:an application of feedback theory. Bone 12:203-217, 1991
PubMed
12) Cavanaugh DJ, Cann CE:Brisk walking dose not stop bone loss in postmenopausal women, Bone 9:201-204, 1988
 
13) Shapes SA:運動と骨の健康(楊 鴻生訳). 骨の健康と栄養科学大事典, eds by Holick MF, Dawson-Hughes B, 乗松尋道総監訳, 岡野登志夫, 森 諭史, 江澤郁子ほか監訳, 西村書店, 東京, 2009, pp.281-296
 
14) 楊 鴻生:osteoporosisの理学療法. 骨・関節・靱帯 2:959-968, 1989
 
15) 楊 鴻生:運動療法. Mod Physician 20:243-248, 2000
 
P.89 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2007
 
2) Matsumoto T, Hagino H, Shiraki M et al:Effect of daily oral minodronate on vertebral fractures in Japa-nese postmenopausal women with established osteoporosis:a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429-1437, 2009
 
3) Liberman UA, Hochberg MC, Geusens P et al:Hip and non-spine fracture risk reductions differ among antiresorptive agents:evidence from randomised controlled trials. Int J Clin Pract 60:1394-1400, 2006
PubMed
4) Cauley JA, Robbins J, Chen Z et al;Women's Health Initiative Investigators:Effects of estrogen plus progestin on risk of fracture and bone mineral density:the Women's Health Initiative randomized trial. JAMA 290:1729-1738, 2003
PubMed
5) Lee WL, Chao HT, Cheng MH et al:Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 60:92-107, 2008
PubMed
6) Abrahamsen B, Vestergaard P:Declining incidence of hip fractures and the extent of use of anti-osteo-porotic therapy in Denmark 1997-2006. Osteoporos Int, 2009, in press
 
P.94 掲載の参考文献
1) 折茂 肇, 林 泰史, 福永仁夫ほか:原発性骨粗鬆症の診断基準(2000年度改訂版). 日骨代謝会誌 18:76-82, 2001
Medical*Online
2) 竹内靖博:骨粗鬆症患者の専門医への紹介のタイミング. 日医師会誌 136:312, 2007
 
3) Brown SA, Guise TA:Drug insight:the use of bisphosphonates for the prevention and treatment of osteoporosis in men. Nat Clin Pract Urol 4:310-320, 2007
PubMed
P.98 掲載の参考文献
1) Black DM, Cummings SR, Karpf DB et al:Fracture Intervention Trial Research Group:Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541, 1996
 
2) Cummings SR, Black DM, Thompson DE et al:Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures:results from the Fracture Intervention Trial. JAMA 280:2077-2082, 1998
PubMed
3) Harris ST, Watts NB, Genant HK et al;Vertebral Efficacy With Risedronate Therapy(VERT)Study Group:Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis:a randomized controlled trial. JAMA 282:1344-1352, 1999
 
4) Reginster J, Minne HW, Sorensen OH et al;Vertebral Efficacy with Risedronate Therapy(VERT)Study Group:Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91, 2000
 
5) McClung MR, Geusens P, Miller PD et al;Hip Intervention Program Study Group:Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340, 2001
 
6) Ettinger B, Black DM, Mitlak BH et al:Multiple Outcomes of Raloxifene Evaluation(MORE)Investigators:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized clinical trial. JAMA 282:637-645, 1999:Erratum in:JAMA 282:2124, 1999
 
7) Cranney A, Wells G, Willan A et al;Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group:Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516, 2002
PubMed
8) Wells GA, Cranney A, Peterson J et al:Alendronate for the primary and secondary prevention of osteo-porotic fractures in postmenopausal women. Cochrane Database Syst Rev(1):CD001155, 2008
 
9) Papapoulos SE, Quandt SA, Liberman UA et al:Meta-analysis of the efficacy of alendronate for the pre-vention of hip fractures in postmenopausal women. Osteoporos Int 16:468-474, 2005
 
10) Cranney A, Guyatt G, Griffith L et al;Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group:Meta-analyses of therapies for postmenopausal osteoporosis. IX:Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578, 2002
PubMed
11) Wells GA, Cranney A, Peterson J et al:Risedronate for the primary and secondary prevention of osteo-porotic fractures in postmenopausal women. Cochrane Database Syst Rev(1):CD004523, 2008
 
12) Matsumoto T, Hagino H, Shiraki M et al:Effect of daily oral minodronate on vertebral fractures in Japa-nese postmenopausal women with established osteoporosis:a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429-1437, 2009
 
P.103 掲載の参考文献
1) Bell KL, Loveridge N, Jordan GR et al:A novel mechanism for induction of increased cortical porosity in cases of intracapsular hip fracture. Bone 27:297-304, 2000
PubMed
2) Szulc P, Duboeuf F, Schott AM et al:Structural determinants of hip fracture in elderly women:re-analy-sis of the data from the EPIDOS study. Osteopors Int 17:231-236, 2006
 
3) Bonnick SL, Beck TJ, Cosman F et al:DXA-based hip structural analysis of once-weekly bisphosphon-ate-treated postmenopausal women with low bone mass. Osteoporos Int 20:911-921, 2009
 
4) Beck TJ, Ruff CB, Warden KE et al:Predicting femoral neck strength from bone mineral data:a struc-tural approach. Invest Radiol 25:6-18, 1990
 
5) Takada J, Beck TJ, Iba K et al:Structural trends in the proximal femur in Japanese postmenopausal women. Bone 41:97-102, 2007
PubMed
6) Greenspan SL, Beck TJ, Resnick NM et al:Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry:a 3-year, double-blind placebo-controlled clinical trial. J Bone Miner Res 20:1525-1532, 2005
PubMed
7) Uusi-Rasi K, Beck TJ, Semanick LM et al:Structural effects of raloxifene on the proximal femur:results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17:575-586, 2006
PubMed
8) Lewiecki EM, Keaveny TM, Kopperdahl DL et al:Once-monthly oral ibandronate improves biomechani-cal determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocr Metab 94:171-180, 2009
 
9) Uusi Rasi K, Semanick LM, Zanchetta JR et al:Effects of teriparatide[rhPTH(1-34)]treatment on struc-tural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948-958, 2005
 
10) Beck TJ, Lewiecki EM, Miller PD et al:Effects of denosumab on the geometty of the proximal femur in postemenopausal women in comparison with alendronate. J Clin Densitom 11:351-359, 2008
 
P.107 掲載の参考文献
1) Kim KJ, Rubash HE, Wilson SC et al:A histologic and biochemical comparison of the interface tissues in cementless and cemented hip prostheses. Clin Orthop Relat Res 287:142-152, 1993
PubMed
2) Kim KJ, Chiba J, Rubash HE:In vivo and in vitro analysis of membranes from hip prostheses inserted without cement. J Bone Joint Surg Am 76:172-180, 1994
PubMed
3) Kim KJ, Itoh T, Tanahashi M et al:Activation of osteoclast-mediated bone resorption by the supernatant from a rabbit synovial cell line in response to polyethylene particles. J Biomed Mater Res 32:3-9, 1996
PubMed
4) Kim KJ, Hijikata H, Itoh T et al:Joint fluid from patients with failed total hip arthroplasty stimulates pit for-mation by mouse osteoclasts on dentin slices. J Biomed Mater Res 43:234-240, 1998
 
5) Kim KJ, Kotake S, Udagawa N et al:Osteoprotegerin inhibits in vitro mouse osteoclasts formation induced by joint fluid from failed total hip arthroplasty. J Biomed Mater Res 58:393-400, 2001
PubMed
6) Kim KJ, Kobayashi Y, Itoh T:Osteolysis model with continuous infusion of polyethylene particles. Clin Orthop Relat Res 352:46-52, 1998
PubMed
7) Iwase M, Kim KJ, Kobayashi Y et al:A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyetylene particles. J Orthop Res 20:499-505, 2002
 
P.111 掲載の参考文献
1) 中村利孝:骨粗しょう薬物治療におけるビスフォスフォネート治療の位置づけ. Med Sci Digest 31:388-391, 2005
 
2) Cranney A, Guyatt G, Krolicki N et al:Osteoporosis Research Advisory Group(ORAG):A meta-analy-sis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 12:140-151, 2001
 
3) Bone HG, Hosking D, Devogelaer JP et al:Alendronate Phase III Osteoporosis Treatment Study Group:Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199, 2004
 
4) Mellstrom DD, Sorensen OH, Goemaere S et al:Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462-468, 2004
PubMed
5) Odvina CV, Zerwekh JE, Rao DS et al:Severely suppressed bone turnover:a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301, 2005
PubMed
6) Mavrokokki T, Cheng A, Stein B et al:Nature and frequency of bisphosphonate-associated osteonecro-sis of the jaws in Australia. J Oral Maxillofac Surg 65:415-423, 2007
 
7) Ott SM:Long-term safety of bisphosphonates. J Clin Endocrinol Metab 90:1897-1899, 2005
PubMed
8) Iba K, Takada J, Hatakeyama N et al:Changes in urinary NTX levels in patients with primary osteoporo-sis undergoing long-term bisphosphonate treatment. J Orthop Sci 13:438-441, 2008
 
9) V骨粗鬆症の治療B. 治療効果の評価と管理b. 骨代謝マーカー. 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006, pp.56-58
 
P.115 掲載の参考文献
1) 折茂 肇:診療所に通院する骨粗鬆症患者の服薬コンプライアンスと腰背部痛の現状. Osteoporosis Jpn 15:9-16, 2007
 
2) 中野哲雄, 鶴上 浩:骨粗鬆症椎体骨折と疼痛. Clin Calcium 11:1147-1152, 2001
 
3) 米田俊之:ビスフォスフォネートの多彩な作用. Med Sci Digest 31:384-387, 2005
 
4) 西角文夫, 中山達雄, 中塚正志:Etidronate(ダイドロネル(R))の鎮痛作用-炎症モデルを用いた検討-. 薬理と臨 26:457-463, 1998
 
5) 宮腰尚久, 粕川雄司:腰背部痛を訴える患者への使用薬. 薬局 58:3262-3266, 2007
Medical*Online
6) 酒井昭典:骨粗鬆症 産業医科大学病院整形外科での実践. ペインクリニック 28(別冊秋):S632-S638, 2007
 
7) 岡野 徹, 萩野 浩:骨粗鬆症 鳥取大学医学部附属病院整形外科での実践. ペインクリニック 28(別冊秋):S639-S647, 2007
 
8) 高桑昌幸:骨粗鬆症患者の急性腰背部痛に対するリセドロネートとカルシトニンの併用療法. Osteopo-rosis Jpn 117:52-54, 2009
 
9) 高桑昌幸:骨粗鬆症診療の実際・私の工夫～服薬継続のための一工夫～. 日本新薬季刊誌 157:9-15, 2008
 
10) 吉村 恵, 伊藤彰敏, 古江秀昌:骨粗鬆症の痛みの発生とカルシトニンによる鎮痛作用. Clin Calcium 11:1153-1157, 2001
 
11) Nevitt MC, Thompson DM, Black DM et al;Fracture Intervention Trial Research Group:Effect of alen-dronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 160:77-85, 2000
 
12) Kakimoto S, Nagakura Y, Tamura S et al:Minodronic acid, a third-generation bisphosphonate, antago-nizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain model. Eur J Pharmacol 589:98-101, 2008
 
13) 加茂 淳:トリガーポイントブロックで腰痛は治る!, 風雲舎, 東京, 2009
 
14) 山崎 謙:リセドロネート投与による短期血清NTXの変化と腰痛の軽減効果の検討. Prog Med 24:1309-1315, 2004
Medical*Online
15) 大林浩幸:原発性骨粗鬆症患者のリセドロネート長期間投与におけるQOL改善効果の検討. 日臨 67:206-212, 2009
Medical*Online
16) 雑賀明宏, 松中秀之:Risedronateによる骨粗しょう症患者の腰痛に対する除痛効果およびQOL改善効果の検討. Osteoporosis Jpn 13:485-490, 2005
 
17) Iwamoto J, Takeda T, Sato Y et al:Effects of alendronate on metacarpal and lumbar bone mineral densi-ty, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol 23:383-389, 2004
 
18) 紺野慎一, 菊地臣一:骨粗鬆症に対する腰背部痛の治療効果. Clin Calcium 15:448-493, 2005
 
19) 太田信孝, 柴田靖章, 伊藤博元:骨粗鬆症患者における腰背部痛に対するrisedronateおよびcalcitoninの除痛効果の検討. 新薬と臨 54:287-293, 2005
Medical*Online
20) Scharla S, Oertel H, Helsberg K et al:Skeletal pain in postmenopausal women with osteoporosis:prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Curr Med Res Opin 22:2393-2402, 2006
 
21) 揚 鴻生:オステオポローシスの運動療法. 関節外科 21:1260-1267, 2002
 
22) 金沢敏勝, 藤本吉範, 奥田晃章ほか:骨粗鬆症椎体骨折偽関節に対する経皮的椎体形成術:手術適応と術後長期成績. 別冊整形外 52:84-89, 2007
 
23) 橋本淳一, 武井 寛, 荻野利彦:骨粗鬆症性椎体偽関節に対する後方進入脊椎短縮骨切り術-超高分子量ポリエチレンケーブルを用いたLuque法. 別冊整形外 52:117-121, 2007
 
24) 吉田 徹:骨粗鬆症性脊椎圧迫骨折に対する積極的保存療法のコツ. MB Orthop 19:1-9, 2006
 
P.121 掲載の参考文献
1) Gerdhem P, Ivaska KK, Alatalo SL et al:Biochemical markers of bone metabolism and prediction of frac-ture in elderly women. J Bone Miner Res 19:386-393, 2004
 
2) 日本骨粗鬆症学会 骨粗鬆症診療における骨代謝マーカーの適正使用に関する検討委員会:骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン(2004年度版). Osteoporosis Jpn 12:191-207, 2004
 
3) Nishizawa Y, Inaba M, Ishii M et al:Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J Bone Miner Metab 26:265-270, 2008
PubMed
4) Yamada S, Inaba M, Kurajoh M et al:Utility of serum tartrate-resistant acid phosphatase(TRACP5b)as a bone resorption marker in patients with chronic kidney disease:independence from renal dysfunction. Clin Endcrinol(Oxf) 69:189-196, 2008
PubMed
5) 西村 順, 荒井紀光, 藤松順一:電気化学発光免疫測定法(ECLIA)による血清中ucOC測定キット「ピコルミ(R)ucOC」の性能検討. Clin Calcium 17:1702-1708, 2007
 
6) Ivaska KK, Gerdhem P, Akesson K et al:Effect of fracture on bone turnover markers:a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 22:1155-1164, 2007
 
7) Delmas PD, Vrijens B, Eastell R et al;Improving Measurements of Persistence on Actonel Treatment(IMPACT)Investigators:Effect of monitoring bone turnover markers on persistence with risedronate treat-ment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296-1304, 2007
 
8) 三木隆己, 中 弘志, 今井弘子ほか:骨代謝マーカーによるアレンドロネートの治療モニタリング-どの程度評価可能か-. Osteoporosis Jpn 12:219-224, 2004
 

[Part4] 治療に注意を要する骨粗鬆症患者さんの治療戦略を探る

P.126 掲載の参考文献
1) Kindblom JM, Gevers EF, Skrtic SM et al:Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors. Bone 36:607-616, 2005
PubMed
2) Miura M, Tanaka K, Komatsu Y et al:A novel interaction between thyroid hormones and 1,25(OH)2D3 in osteoclast formation. Biochem Biophys Res Commun 291:987-994, 2002
PubMed
3) Kanatani M, Sugimoto T, Sowa H et al:Thyroid hormone stimulates osteoclast differentiation by a mecha-nism independent of RANKL-RANK interaction. J Cell Physiol 201:17-25, 2004
 
4) Vestergaard P, Mosekilde L:Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis. Thy-roid 13:585-593, 2003
 
5) Pantazi H, Papapetrou PD:Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 85:1099-1106, 2000
PubMed
6) Cummings SR, Nevitt MC, Browner WS et al;Study of Osteoporotic Fractures Research Group:Risk factors for hip fracture in white women. N Engl J Med 332:767-773, 1995
 
7) Kumeda Y, Inaba M, Tahara H et al:Persistent increase in bone turnover in Graves'patients with subclini-cal hyperthyroidism. J Clin Endocrinol Metab 85:4157-4161, 2000
 
P.130 掲載の参考文献
1) 大島久二:ステロイドの副作用と対策. 今日の治療指針, 山口 徹, 北原光男, 福井次夫編, 医学書院, 東京, 2009, pp.637-638
 
2) 大島久二, 秋谷久美子, 田中郁子:ステロイド薬. 綜合臨 57:2883-2888, 2008
Medical*Online
3) McDonough AK, Curtis JR, Saag KG:The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 20:131-137, 2008
PubMed
4) Vestergaard P, Rejnmark L, Mosekilde L:Fracture risk associated with systemic and topical corticosteroids, J Inten Med 257:374-384, 2005
 
5) 田中郁子, 大島久二:ステロイド性骨粗鬆症の診断と治療に関する縦断研究. Osteoporosis Jpn 11:11-14, 2003
 
6) Nawata H, Soen S, Takayanagi R et al;Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis:Guidelines on the management and treatment of glucocorticoid-induced osteo-porosis of the Japanese Society for Bone and Mineral Research(2004). J Bone Miner Metab 23:105-109, 2005
 
7) 大島久二, 田中郁子:ステロイド性骨粗鬆症とその管理--SERMを含めて. 産婦治療 94:935-939, 2007
Medical*Online
8) 大島久二:ステロイド性骨粗鬆症と骨代謝マーカー. リウマチ科 29:406-411, 2003
 
9) 大島久二, 田中郁子:ステロイド薬は関節リウマチに使用すべきか. medicina 42:800-802, 2005
 
10)大島久二, 田中郁子:ステロイド使い方のコツ--内服剤の使い方. 研修医のためのステロイドの使い方のコツ, 川合眞一編, 文光堂, 東京, 2009, pp.20-31
 
P.134 掲載の参考文献
1) 岡崎亮:糖尿病と骨粗鬆症. 治療 91:1871-1875, 2009
Medical*Online
2) Nathan DM, Buse JB, Davidson MB et al;American Diabetes Association;European Association for Study of Diabetes:Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy:a consensus statement of the American Diabetes Associa-tion and the European Association for the Study of Diabetes. Diabetes Care 32:193-203, 2009
 
P.143 掲載の参考文献
1) Moe S, Drueke T, Cunningham J et al;Kidney Disease:Improving Global Outcomes(KDIGO):Difini-tion, evaluation, and classification of renal osteodystrophy:a position statement from Kidney Disease:Improving Global Outcome(KDIGO). Kideny Int 69:1945-1953, 2006
 
2) 後藤俊介, 深川雅史:腎機能障害に伴う二次性副甲状腺機能亢進症の発症機序. Clin Calcium 19:809-814, 2009
 
3) Ganesh SK, Stack AG, Levin NW et al:Association of elevated serum PO4, CaxPO4 product, and para-thyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
 
4) Slinin Y, Foley RN, Collins AJ:Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients:the USRDS wave 1, 3, and 4 study. J Am Soc Nephrol 16:1788-1793, 2005
 
5) 濱野高行:血清リン濃度と透析患者の予後. Clin Calcium 19:174-179, 2009
 
6) Noordzij M, Korevaar JC, Boeschoten EW et al;Netherlands Cooperative Study on the Adequacy of Dialysis(NECOSAD)Study Group:The Kidney Disease Outcomes Quality Initiative(K/DOQI)Guideline for Bone Metabolism and Disease in CKD:association with mortality in dialysis patients. Am J Kidney Dis 46:925-932, 2005
 
7) 社団法人日本透析医学会:透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39:1435-1455, 2006
 
P.147 掲載の参考文献
1) Minsker DH, Manson JM, Peter CP:Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121:217-223, 1993
PubMed
2) Patlas N, Golomb G, Yaffe P et al:Transplacental effects of bisphosphonates on fetal skeletal ossifica-tion and mineralization in rats. Teratology 60:68-73, 1999
 
3) McKenzie AF, Budd RS, Yang C et al:Technetium-99 m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med 35:1338-1341, 1994
 
4) Harsch IA, Hubner RH, Hahn EG et al:Osteoporosis and multiple pregnancy--a case report with posi-tive outcome. Med Klin(Munich) 96:402-407, 2001
 
5) Munns CF, Rauch F, Ward L et al:Maternal and fetal outcome after long-term pamidronate treatment before conception:a report of two cases. J Bone Miner Res 19:1742-1745, 2004
 
6) Chan B, Zacharin M:Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dys-plasia and osteogenesis imperfecta before conception:a report of four cases. J Clin Endocrinol Metab 91:2017-2020, 2006
 
7) O'Sullivan SM, Grey AB, Singh R et al:Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 17:1008-1012, 2006
PubMed
8) Ornoy A, Wajnberg R, Diav-Citrin O:The outcome of pregnancy following pre-pregnancy or early preg-nancy alendronate treatment. Reprod Toxicol 22:578-579, 2006
PubMed
9) Levy S, Fayez I, Taguchi N et al:Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428-430, 2009
PubMed
10) Djokanovic N, Klieger-Grossmann C, Koren G:Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 30:1146-1148, 2008
PubMed
11) 碓井孝志, 神村秀隆, 瀬谷一浩ほか:14C-ミノドロン酸水和物をラットに静脈内投与したときの分布, 代謝および排泄. 薬理と臨 18:S-191-S-211, 2008
 
P.150 掲載の参考文献
1) Furukawa N, Iwakiri R, Koyama T et al:Proportion of reflux esophagitis in 6010 Japanese adults:pro-spective evaluation by endoscopy. J Gastroenterol 34:441-444, 1999
 
2) Yamaguchi T, Sugimoto T, Yamada H et al:The presence and severity of vertebral fractures is associated with the presence of esophageal hiatal hernia in postmenopausal women. Osteoporos Int 13:331-336, 2002
PubMed
3) Yamaguchi T, Sugimoto T, Yamauchi M et al:Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women. J Bone Miner Metab 23:36-40, 2005
PubMed
4) Yang YX, Lewis JD, Epstein S et al:Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947-2953, 2006
PubMed
5) Reid DM, Hosking D, Kendler D et al:A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis:24-month results from FACTS International. Int J Clin Pract 62:575-584, 2008
 
6) Liberman UA, Hochberg MC, Geusens P et al:Hip and non-spine fracture risk reductions differ among antiresorptive agents:evidence from randomized controlled trials. Int J Clin Pract 60:1394-1400, 2006
PubMed
7) Gertz BJ, Holland SD, Kline WF et al:Studies of the oral bioavailability of alendronate, Clin Pharmacol Ther 58:288-298, 1995
PubMed
8) 山根雄幸, 津森道弘, 山口徹ほか:高齢者骨粗鬆症患者の食道胃逆流症(GERD)および誤嚥性肺炎に対するエルカトニンの効果の検討. Osteoporosis Jpn 16:69-71, 2008
Medical*Online

[Part5] きめの細かい服薬指導のために知識を得る

P.157 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症治療の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006
 
2) Ettinger MP, Gallagher R, MacCosbe PE:Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 12:522-528, 2006
PubMed
3) Rossouw JE, Anderson GL, Prentice RL et al;Writing group for the Women's Health Initiative Investigators:Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
 
4) Ettinger B, Black DM, Mitlak BH et al;Multiple Outcomes of Raloxifene Evaluation(MORE)Investigators:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized clinical trial, JAMA 282:637-645, 1999
PubMed
5) Bone HG, Hosking D, Devogelaer J-P et al:Alendronate Phase III Osteoporosis Treatment Study Group:Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199, 2004
 
6) Sorensen OH, Crawford GM, Mulder H et al:Long-term efficacy of risedronate:a 5-year placebo-controlled clinical experience. Bone 32:120-126, 2003
PubMed
7) Hochberg MC, Greenspan S, Wasnich RD et al:Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592, 2002
PubMed
P.163 掲載の参考文献
1) 田中郁子, 早川克彦, 大島久二:アレンドロネートの服用継続率の検討--クリニックにおける骨粗鬆症診療実態調査. Osteoporosis Jpn 11:252-255, 2003
 
2) Peter CP, Kindt MV, Majka JA:Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci 43:1009-1015, 1998
PubMed
3) Bauer DC, Black D, Ensrud K et al:Upper gastrointestinal tract safety profile of alendronate:the fracture intervention trial. Arch Intern Med 160:517-525, 2000
PubMed
4) Cryer B, Bauer DC:Oral bisphosphonates and upper gastrointestinal tract problems:what is the evidence? Mayo Clin Proc 77:1031-1043, 2002
PubMed
5) Lanza F, Schwartz H, Sahba B et al:An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 95:3112-3117, 2000
PubMed
6) Bauer DC, Black D, Ensrud K et al:Upper gastrointestinal tract safety profile of alendronate:the fracture intervention trial. Arch Intern Med 160:517-525, 2000
PubMed
7) Kishimoto H, Fukunaga M, Kushida K et al;Risedronate Phase III Research Group:Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis:a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405-413, 2006
 
P.168 掲載の参考文献
1) Nawata I, Soen S, Takayanagi R et al;Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis:Guidelines on the management and treatment of glucocorticoid-induced osteo-porosis of the Japanese Society for Bone and Mineral Research(2004). J Bone Miner Metab 23:105-109, 2005
 
2) van Staa TP, Leufkens HG, Abenhaim L et al:Use of oral corticosteroids and risk of fracture. J Bone Miner Res 15:993-1000, 2000
PubMed
3) van Staa TP, Leufkens HG, Cooper C:The epidemiology of corticosteroid-induced osteoporosis:a meta-analysis. Osteoporos Int 13:777-787, 2002
PubMed
4) Kanis JA, Stevenson M, McCloskey EV et al:Glucocorticoid-induced osteoporosis:A systematic review and cost-utility analysis. Health Technol Assess 11:iii-iv, ix-xi, 1-231, 2007
 
5) de Nijs RN, Jacobs JW, Algra A et al:Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues:a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589-602, 2004
PubMed
6) 田中郁子, 大島久二:ステロイド性骨粗鬆症の診断と治療に関する縦断研究, Osteoporosis Jpn 11:11-14, 2003
 
7) Saag KG, Shane E, Boonen S et al:Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039, 2007
PubMed
8) Djokanovic N, Klieger-Grossmann C, Koren G:Dose treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 30:1146-1148, 2008
 
9) Inoue Y, Shimojo N, Suzuki S et al:Efficacy of intravenous alendronate for the treatment of glucocorti-coid-induced osteoporosis in children with autoimmune diseases. Clin Rheumatol 27:909-912, 2008
 
P.172 掲載の参考文献
1) Patel BV, Remigio-Baker RA, Mehta D et al:Effect of initial antihypertsnsive drug class on patient persis-tence and compliance in a usual-care setting in the United States. J Clin Hypertens(Greenwich) 9:692-700, 2007
 
2) 桐山 健:一般臨床における骨粗鬆症治療薬コンプライアンス(アドヒアランス)の現状と改善対策. 骨粗鬆症治療 7:127-131, 2008
Medical*Online

[Part6] 骨粗鬆症治療における各科の役割を探る

P.178 掲載の参考文献
1) Roelofs AJ, Thompson K, Gordon S et al:Molecular mechanisms of action of bisphosphonates:current status. Clin Cancer Res 12:6222s-6230s, 2006
PubMed
2) Marx RE:Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws:a growing epidemic. J Oral Maxillofac Surg 61:1115-1117, 2003
PubMed
3) Ruggiero SL, Mehrotra B, Rosenberg TJ et al:Osteonecrosis of the jaws associated with the use of bisphosphonates:a review of 63 cases. J Oral Maxillofac Surg 62:527-534, 2004
 
4) 島原政司, 有吉靖則, 今井 裕ほか:ビスフォスフォネート投与と関連性があると考えられた顎骨骨髄炎ならびに顎骨壊死に関する調査. 日口外誌 53:594-602, 2007
 
5) Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws:American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376, 2007
 
6) Ruggiero SL, Dodson TB, Assael LA et al:American Association of Oral and Maxillofacial Surgeons posi-tion paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 67(5 Suppl):2-12, 2009
 
7) Khosla S, Burr D, Cauley J et al:Bisphosphonate-associated osteonecrosis of the jaw:report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491, 2007
 
8) Khan AA, Sandor GK, Dore E et al:Canadian consensus practice guidelines for bisphosphonate associ-ated osteonecrosis of the jaw. J Rheumatol 35:1391-1397, 2008
 
P.182 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン2006年版, 骨粗鬆症の予防と治療ガイドライン作成委員会編, ライフサイエンス出版, 東京, 2006
 
2) Kanis JA, Oden A, Johnell O et al:The use of clinical risk factors enhances the performance of BMD in the prediction of hip fracture and osteoporotic fractures in men and women. Osteopros Int 18:1033-1046, 2007
PubMed
P.185 掲載の参考文献
1) 林 泰史:日本骨粗鬆症学会による啓発セミナーの有用性と臨床医の骨粗彩症に関する診療実態--EBMセミナー参加医師に対するアンケート調査結果から. Osteoporosis Jpn 13:467-474, 2005
 
2) 林 泰史:高齢者の脊柱変形とQOL-全人的な観点から-. 第13回腰痛シンポジウム講演会記録集, インターメッド, 東京, 2003, pp.18-28
 
3) Schlaich C, Minne HW, Bruckner T et al:Reduced pulmonary function in patients with spinal osteo-porotic fractures. Osteoporos Int 8:261-267, 1998
 
4) 白木正孝:亀背の内科的QOL. Osteoporosis Jpn 9:489-492, 2001
 
5) Cauley JA, Thompson DE, Ensrud KC et al:Risk of mortality following clinical fractures. Osteoporos Int 11:556-561, 2000
PubMed
6) Cooper C, Atkinson EJ, Jacobsen SJ et al:Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001-1005, 1993
PubMed
7) 中村耕三:ロコモティブシンドロームは要介護リスク. メディカル朝日 38:16-17, 2009/3
 
P.189 掲載の参考文献
1) Kuroda T, Shiraki M, Tanaka S et al:Contributions of 25-hydroxyvitamin D, co-morbidities and mass to mortality in Japanese postmenopausal women. Bone 44:168-172, 2009
PubMed
2) Orito S, Kuroda T, Onoe Y et al:Age-related distribution of bone and skeletal parameters in 1,322 Japa-nese young women. J Bone Miner Metab 27:698-704, 2009
 
3) 綾部琢哉:ダイエット. 産と婦 75:550-554, 2008
Medical*Online
4) 小栗和雄, 藤井勝紀, 石垣 亨:推定体脂肪量の初経発来臨界期に関する検証. 発育発達研 32:7-14, 2006
 
5) 丸山哲夫, 小田英之, 西川明花ほか:排卵障害. 産と婦 75:527-536, 2008
 
6) Miyabara Y, Onoe Y, Harada A et al:Effect of physical activity and nutrition on bone mineral density in young Japanese women. J Bone Miner Metab 25:414-418, 2007
 
7) Kuroda T, Onoe Y, Miyabara Y et al:Influence of maternal genetic and lifestyle factors on bone mineral density in adolescent daughters:a cohort study in 387 Japanese daughter-mother pairs. J Bone Miner Metab 27:379-385, 2009
 
P.194 掲載の参考文献
1) 野村一俊:地域連携クリティカルパスの活用効果. 国立病機構熊本医療セ医誌 8:1-6, 2007
 
2) 野村一俊:大腿骨近位部骨折における地域医療連携-地域連携クリティカルパスとかかりつけ医の関わり. 日本医事新報 4406:44-47, 2008
Medical*Online

書評

最近チェックした商品履歴

Loading...